ETAFENONE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H27NO2.ClH
Molecular Weight	361.906
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCN(CC)CCOC1=CC=CC=C1C(=O)CCC2=CC=CC=C2

InChI

InChIKey=BYWIEEUABBZFEE-UHFFFAOYSA-N

InChI=1S/C21H27NO2.ClH/c1-3-22(4-2)16-17-24-21-13-9-8-12-19(21)20(23)15-14-18-10-6-5-7-11-18;/h5-13H,3-4,14-17H2,1-2H3;1H

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23 | https://www.ncbi.nlm.nih.gov/pubmed/238542
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/6482088 | https://www.ncbi.nlm.nih.gov/pubmed/582134 | https://www.ncbi.nlm.nih.gov/pubmed/469443 | https://www.ncbi.nlm.nih.gov/pubmed/94412 | http://www.drugfuture.com/chemdata/etafenone.html | https://www.ncbi.nlm.nih.gov/pubmed/582134 | https://www.ncbi.nlm.nih.gov/pubmed/94412 | https://www.ncbi.nlm.nih.gov/pubmed/1037264 | https://www.ncbi.nlm.nih.gov/pubmed/1786372

Etafenone is an antiarrhythmic and coronary vasodilator drug. Etafenone exerts negative inotropic action on myocardium. It is able to block calcium channels. As a coronary vasodilator which produces a decrease in the heart rate and myocardial oxygen consumption, etafenone has been used in the therapy of ischemic heart disease.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D1 receptor 101 Target ID: CHEMBL3071 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10888308	Binding Agent 1064	2.43 µM [Ki]
Dopamine D2 receptor 297 Target ID: CHEMBL3427 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10888308	Binding Agent 1064	3.92 µM [Ki]
Muscarinic acetylcholine receptor 160 Target ID: CHEMBL2097162 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10888308	Binding Agent 1064	0.184 µM [Ki]
vascular smooth muscle contraction 5 Target ID: GO:0014829 Sources: http://www.kegg.jp/entry/D01440 \| https://www.ncbi.nlm.nih.gov/pubmed/23 \| https://www.ncbi.nlm.nih.gov/pubmed/238542	Inhibitor 8297
Voltage-gated calcium channel 37 Target ID: CHEMBL2363032 Sources: http://www.drugfuture.com/chemdata/etafenone.html \| https://www.ncbi.nlm.nih.gov/pubmed/582134 \| https://www.ncbi.nlm.nih.gov/pubmed/94412 \| https://www.ncbi.nlm.nih.gov/pubmed/1037264 \| https://www.ncbi.nlm.nih.gov/pubmed/1786372	Blocker 537

Conditions

Condition	Modality	Targets	Highest Phase	Product
Angina pectoris 106 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6482088	Primary		Approved 8429	DIALICOR Approved Use Unknown

PubMed

Title	Date	PubMed
[Pharmacological and toxicological studies on the effect characterization of etafenone].	1969 Oct	5395365
Effects of etafenone and antiarrhythmic drugs on Na and Ca channels of guinea pig atrial muscle.	1979 Sep-Oct	94412

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Parenteral

In Vitro Use Guide

After etafenone 1 uM, there was a significant prolongation of the time to the detectable or the maximum increase in NADH fluorescence in isolated perfused guinea pig heart

Name

Type

Language

ETAFENONE HYDROCHLORIDE

Common Name

English

NSC-166350

Code

English

Etafenone hydrochloride [WHO-DD]

Common Name

English

ETAFENONE HCL

Common Name

English

HEPTAPHENONE

Common Name

English

ETAFENONE HYDROCHLORIDE [JAN]

Common Name

English

LG-11457

Code

English

2'-(2-DIETHYLAMINOETHOXY)-3-PHENYLPROPIOPHENONE HYDROCHLORIDE

Systematic Name

English

ETAFENONE HYDROCHLORIDE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C48149